Loading...
This record has been deleted. Since it is linked to a published record, it is available here for reference purposes only.
Click here to view the deleted recordThis document has been updated. This is not the latest published version. Click here to view the latest version of the record.
Living Modified Organism
(LMO)
The image below identifies the LMO through its unique identifier, trade name and a link to this page of the BCH. Click on it to download a larger image on your computer. For help on how to use it go to the LMO quick-links page.
VECTORMUNE® FP MG Vaccine
EN
FP MG
No
-
Person:Dr Alexis Henry Gaetan GouxPresident of CIBio,Rua Manuel Joaquim Filho, 303 Pulínia - SPPaulínia, São Paulo
13140-000, BrazilPhone: 551938337700,Fax: 55193833-7722,Email: alexisgoux@ceva.com,Website: http://www.ceva.com.br/,Related OrganizationCeva Saúde Animal Ltda (CEVA)Private sector (business and industry)Rua Manuel Joaquim Filho, 303 Pulínia - SPPaulínia, São Paulo
13140-000, BrazilPhone: 551938337700,Fax: 55193833-7722,Email: alexisgoux@ceva.com,Website: http://www.ceva.com.br/,
VECTORMUNE® FP MG is a genetically engineered live virus vaccine for the vaccination of chickens as an aid in the prevention of fowl pox and Mycoplasma gallisepticum. The fowl pox vaccine has been genetically engineered to contain and express key protective Mycoplasma gallisepticum bacterial antigens.
EN
The term “Recipient organism” refers to an organism (either already modified or non-modified) that was subjected to genetic modification, whereas “Parental organisms” refers to those that were involved in cross breeding or cell fusion.
-
BCH-ORGA-SCBD-105171-4 Organism Fowlpox virus (FOWPV)Viruses
EN
pUC18
EN
- Other (Homologous Recombination)
Some of these genetic elements may be present as fragments or truncated forms. Please see notes below, where applicable.
-
BCH-GENE-SCBD-105360-1 mgc3 gene | Mycoplasma gallisepticum (MG, MYCGL)Protein coding sequence | Production of medical or pharmaceutical compounds (human or animal) (Vaccines)
-
BCH-GENE-SCBD-105411-1 MG 40k antigen gene | Mycoplasma gallisepticum (MG, MYCGL)Protein coding sequence | Production of medical or pharmaceutical compounds (human or animal) (Vaccines)
A 3kb Hpal-Spel fragment of the FPV genome was inserted into a EcoR1-HindIII site of a pUC18 vector. The homologous recombination site may be interrupting a possible open reading frame but is thought to be non-essential for viral replication and has no known function in the FPV.
A 175bp EcoRV fragment of the FPV genome was removed from this construct and replaced with the MG 40K and mcg3 coding sequences.
Regulatory sequences were also inserted into the vector. The MG 40K and mcg3 genes were each coupled with a synthetic Ps promoter, which emulates the consensus early/late promoter of poxvirus. A termination sequence derived from the gB gene of the Marek Disease Virus was also inserted into the pUC18 vector.
Furthermore, a MDV gB transit signal sequence was added to the 3' terminus of the of MG 40K and mcg3 coding sequences to ensure localisation to the cell membrane.
This construct and the attenuated parental FPV strain were co-transformed into chicken embryo fibroblasts (CEF) and incubated under conditions that favour homologous recombination.
After transfection, viral particles were cultivated from the chicken embryo fibroblasts and assayed for expression of MG 40K and mcg3 proteins. Plaques expressing MG 40K and mcg3 proteins were isolated and selected until the pure recombined virus was obtained.
EN
A 175bp EcoRV fragment of the FPV genome was removed from this construct and replaced with the MG 40K and mcg3 coding sequences.
Regulatory sequences were also inserted into the vector. The MG 40K and mcg3 genes were each coupled with a synthetic Ps promoter, which emulates the consensus early/late promoter of poxvirus. A termination sequence derived from the gB gene of the Marek Disease Virus was also inserted into the pUC18 vector.
Furthermore, a MDV gB transit signal sequence was added to the 3' terminus of the of MG 40K and mcg3 coding sequences to ensure localisation to the cell membrane.
This construct and the attenuated parental FPV strain were co-transformed into chicken embryo fibroblasts (CEF) and incubated under conditions that favour homologous recombination.
After transfection, viral particles were cultivated from the chicken embryo fibroblasts and assayed for expression of MG 40K and mcg3 proteins. Plaques expressing MG 40K and mcg3 proteins were isolated and selected until the pure recombined virus was obtained.
EN
- Vaccine
EN
EN
- Vectormune® FP-MG - Biomune Company [ English ]
- Vectormune® FP-MG - CTNBio [ English ]
- A safety assessment of a fowlpox-vectored Mycoplasma gallisepticum vaccine in chickens [ English ]
| Record type | Field | Record(s) | |
|---|---|---|---|
| Country's Decision or any other Communication | LMO identification | 2 | |
| Risk Assessment generated by a regulatory process | Living modified organism(s) | 1 | |